Trial intelligence / Profile preview

KRd consolidation to induce or re-induce MRD negativity after first autologous stem cell transplant in multiple myeloma

2016-004778-16Phase 2Terminated

Sponsor
Ordensklinikum Linz
Start
Dec 2017
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label trial of carfilzomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Ordensklinikum Linz. Started Dec 2017; status: terminated.

02

Drugs

carfilzomiblenalidomidedexamethasone
03

Conditions

multiple myeloma (MM)

Beyond the preview

Go deeper on 2016-004778-16.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2016-004778-16.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call